OncLiveExpert Discusses Promise of Immunotherapy in Genitourinary CancersOncLiveIn the treatment of genitourinary (GU) cancers, immunotherapy continues to move toward the frontline setting. Charles Drake, MD, PhD, says he is optimistic about the future… Continue reading
|
Creative Medical Technology Holdings Appoints Internationally Renowned Stem Cell Pioneer as Chief Scientific Officer
Yahoo Finance Dr. Ichim will lead development of the Company’s clinical stage CaverStemTM personalized stem cell therapy for erectile dysfunction, as well as advance preclinical and eventually clinical studies on the Company’s universal donor AmnioStemTMstem cell … |
|
Edited Transcript of EDIT earnings conference call or presentation 7-Mar-17 10:00pm GMT
Yahoo Finance Beyond Cas9, we announced in December the addition of an exclusive global license to Cpf1, which is the only other CRISPR nucleus system that’s been shown to work efficiently and specifically in human cells. Cpf1 meaningfully advances our ability to … |
STAT |
Few people actually benefit from ‘breakthrough’ cancer immunotherapy
STAT When immunotherapy works, the result is terrific, even life-changing. Today, though, only a tiny minority of patients expected to die from cancer will benefit from immunotherapy. As is often the case, hype sadly exceeds evidence, creating … Roy S. Herbst, MD, PhD, on Lung Cancer With Immune Checkpoints: Promising CombinationsNewswise (press release) |
|
Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA
P&T Community THINK (THerapeutic Immunotherapy with NKR-2) is a multinational (EU/US) open-label Phase Ib study to assess the safety and clinical activity of multiple administrations of autologous CAR–T NKR-2 cells in seven refractory cancers, including five solid … |